Evidence map›Paper›PMID 32793387›Full record

ArticleRegenerative biomaterials2020

Liang Chen, Lina Wei, Anliang Shao, Liming Xu

Open access · goldAbstract read
In one paragraph

Article in Regenerative biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Regenerative biomaterials · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Liang ChenDepartment of Medical Device, National Institutes for Food and Drug Control, Huatuo Road 31, Biomedical Production Zone, Daxing District, 102629 Beijing, China.ORCID 0000-0002-6397-0931
Lina WeiDepartment of Medical Device, National Institutes for Food and Drug Control, Huatuo Road 31, Biomedical Production Zone, Daxing District, 102629 Beijing, China.
Anliang ShaoDepartment of Medical Device, National Institutes for Food and Drug Control, Huatuo Road 31, Biomedical Production Zone, Daxing District, 102629 Beijing, China.
Liming XuDepartment of Medical Device, National Institutes for Food and Drug Control, Huatuo Road 31, Biomedical Production Zone, Daxing District, 102629 Beijing, China.
National Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The xenogeneic decellularized corneal matrix (DCM) was expected to be used in lamellar keratoplasty in clinic as the substitute of allogeneic cornea. After decellularization treatment, the remaining risk of xenograft rejection needed to be assessed. The galactose-α1,3-galactose, as the most abundant and closely rejection-related xenogeneic antigen, should be one of the important factors concerned in immunological evaluation. In this study, residual αGal in the DCM was first determined by an enzyme-linked immunosorbent assay method with qualified accuracy and specificity. Then the DCM was implanted subcutaneously into the α1,3-galactosyltransferase gene-knockout (GTKO) mice, accompanied by the implantation in the wild-type C57BL/6 mice as a comparison. The total serum antibody levels, anti-Gal antibody levels, inflammatory cytokines and ratios of splenic lymphocyte subtypes were detected and the histopathological analysis of implants were performed to systematically evaluate the immune responses. The experimental result showed the fresh porcine corneal matrix samples had (9.90 ± 1.54) × 10

Indexed as

decellularized corneal matrixgalactose-α1,3-galactose (αGal)GTKO miceimmune risk

Identifiers

PMID32793387
PMCPMC7414996
OpenAlexW3037376804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.